ZNF184

Summary

ZNF184 (zinc finger protein 184, HGNC:12975) is a protein-coding gene on chromosome 6p22.1, encoding Zinc finger protein 184 (Q99676). May be involved in transcriptional regulation.

The protein encoded by this gene is predicted to be a Kruppel C2H2-type zinc-finger protein family member. Sequence analysis predicts that the protein contains two Kruppel associated box (KRAB) boxes in the N-terminus and highly conserved zinc finger motifs at the C-terminus. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 7738 — RefSeq curated summary.

At a glance

• GWAS associations: 41
• Clinical variants (ClinVar): 63 total
• MANE Select transcript: NM_001318891

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12975
Approved symbol	ZNF184
Name	zinc finger protein 184
Location	6p22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000096654
Ensembl biotype	protein_coding
OMIM	602277
Entrez	7738

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000211936, ENST00000377419, ENST00000683788, ENST00000881542

RefSeq mRNA: 5 — MANE Select: NM_001318891 NM_001318891, NM_001318892, NM_001318893, NM_001347832, NM_007149

CCDS: CCDS4624

Canonical transcript exons

ENST00000683788 — 6 exons

Exon	Start	End
ENSE00001175148	27456826	27456921
ENSE00001366749	27467853	27467920
ENSE00001383362	27457283	27457409
ENSE00001389837	27472288	27472433
ENSE00003918260	27450747	27453260
ENSE00003920979	27472729	27473105

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 93.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.8758 / max 114.8289, expressed in 1592 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
72377	4.2709	1520
72371	0.6527	207
72376	0.2936	137
72372	0.2836	149
72374	0.1757	78
72373	0.1309	50
72375	0.0683	16

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	93.60	gold quality
sperm	CL:0000019	91.62	gold quality
hair follicle	UBERON:0002073	90.47	silver quality
male germ cell	CL:0000015	89.38	gold quality
middle temporal gyrus	UBERON:0002771	89.29	gold quality
endothelial cell	CL:0000115	89.27	gold quality
epithelium of nasopharynx	UBERON:0001951	88.88	gold quality
germinal epithelium of ovary	UBERON:0001304	88.23	gold quality
ganglionic eminence	UBERON:0004023	86.86	gold quality
gingival epithelium	UBERON:0001949	86.41	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.28	gold quality
oocyte	CL:0000023	86.26	gold quality
visceral pleura	UBERON:0002401	86.14	gold quality
CA1 field of hippocampus	UBERON:0003881	85.85	gold quality
parietal pleura	UBERON:0002400	85.42	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.40	gold quality
ventricular zone	UBERON:0003053	85.23	gold quality
nephron tubule	UBERON:0001231	85.21	gold quality
secondary oocyte	CL:0000655	85.14	gold quality
pleura	UBERON:0000977	84.89	gold quality
gingiva	UBERON:0001828	84.31	gold quality
embryo	UBERON:0000922	83.45	gold quality
palpebral conjunctiva	UBERON:0001812	83.32	gold quality
cortical plate	UBERON:0005343	82.91	gold quality
superior frontal gyrus	UBERON:0002661	82.79	gold quality
entorhinal cortex	UBERON:0002728	82.73	gold quality
primary visual cortex	UBERON:0002436	82.50	gold quality
eye	UBERON:0000970	81.27	gold quality
esophagus squamous epithelium	UBERON:0006920	80.99	gold quality
postcentral gyrus	UBERON:0002581	80.63	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.42

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
CDKN2A

JASPAR motifs

Motif	Name	Family
MA2120.1	ZNF184	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:27852650

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

46 targeting ZNF184, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-2053	99.57	69.15	1635

Literature-anchored findings (GeneRIF, showing 3)

• We found that 6p22.1 (rs6904596, ZNF184) was associated with both lung cancer and blood triglycerides. (PMID:27565901)
• Association between ZNF184 and symptoms of Parkinson’s disease in southern Chinese. (PMID:32125537)
• Long intergenic non-protein coding RNA 00858 participates in the occurrence and development of esophageal squamous cell carcinoma through the activation of the FTO-m6A-MYC axis by recruiting ZNF184. (PMID:36868327)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf646	ENSDARG00000061424
danio_rerio	si:dkey-154p10.3	ENSDARG00000068366
danio_rerio	si:dkey-89b17.4	ENSDARG00000075545
danio_rerio	zgc:66472	ENSDARG00000075916
danio_rerio	si:ch211-148l7.4	ENSDARG00000094469
danio_rerio	znf576.1	ENSDARG00000097819
drosophila_melanogaster	az2	FBGN0025185
drosophila_melanogaster	CG2129	FBGN0030008
drosophila_melanogaster	CG1602	FBGN0033186
drosophila_melanogaster	indra	FBGN0035213
drosophila_melanogaster	CG30020	FBGN0050020
drosophila_melanogaster	mld	FBGN0263490

Paralogs (36): ZNF302 (ENSG00000089335), CTCF (ENSG00000102974), ZNF574 (ENSG00000105732), ZBTB24 (ENSG00000112365), ZNF142 (ENSG00000115568), CTCFL (ENSG00000124092), ZNF473 (ENSG00000142528), ZNF827 (ENSG00000151612), ZNF689 (ENSG00000156853), ZNF208 (ENSG00000160321), ZNF91 (ENSG00000167232), ZNF526 (ENSG00000167625), ZNF764 (ENSG00000169951), ZNF747 (ENSG00000169955), ZNF282 (ENSG00000170265), ZNF160 (ENSG00000170949), ZNF497 (ENSG00000174586), ZBTB34 (ENSG00000177125), ZNF771 (ENSG00000179965), ZNF48 (ENSG00000180035), ZNF594 (ENSG00000180626), ZBTB37 (ENSG00000185278), ZFP92 (ENSG00000189420), ZNF107 (ENSG00000196247), ZNF729 (ENSG00000196350), ZNF569 (ENSG00000196437), ZNF420 (ENSG00000197050), ZNF785 (ENSG00000197162), ZNF665 (ENSG00000197497), ZNF181 (ENSG00000197841), ZNF347 (ENSG00000197937), ZNF84 (ENSG00000198040), ZBTB48 (ENSG00000204859), ZNF845 (ENSG00000213799), ZNF99 (ENSG00000213973), ZNF688 (ENSG00000229809)

Protein

Protein identifiers

Zinc finger protein 184 — Q99676 (reviewed: Q99676)

All UniProt accessions (1): Q99676

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Tissue specificity. Predominant expression in testis.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (5): NP_001305820, NP_001305821, NP_001305822, NP_001334761, NP_009080 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050331	Zinc_finger_PRDM4/PRDM1/PRDM14	Family

Pfam: PF00096, PF01352, PF13465

UniProt features (37 total): zinc finger region 19, sequence conflict 9, modified residue 3, chain 1, domain 1, region of interest 1, compositionally biased region 1, cross-link 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99676-F1	72.56	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 117, 122, 199, 206

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 117 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, CREBP1_Q2, BROWNE_HCMV_INFECTION_12HR_UP, CREB_Q4, MODULE_206, E4F1_Q6, ATF3_Q6, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA, FISCHER_DREAM_TARGETS, LEF1_Q6, NRF2_01, MODULE_397, ATF_01

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), sequence-specific DNA binding (GO:0043565), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
DNA binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

764 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF184	POM121L2	Q96KW2	571
ZNF184	PRSS16	Q9NQE7	432
ZNF184	ITPKB	P27987	430
ZNF184	COMMD5	Q9GZQ3	389
ZNF184	OBI1	Q5W0B1	370
ZNF184	HMGN4	O00479	369
ZNF184	RPS7	P23821	361
ZNF184	PGBD1	Q96JS3	359
ZNF184	C8orf58	Q8NAV2	358
ZNF184	SORBS3	O60504	324
ZNF184	TMEM141	Q96I45	323
ZNF184	ABT1	Q9ULW3	323
ZNF184	TMEM121B	Q9BXQ6	315
ZNF184	DPY19L4	Q7Z388	311
ZNF184	EMILIN2	Q9BXX0	307

IntAct

68 interactions, top by confidence:

A	B	Type	Score
ZNF169	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF324B	ZNF316	psi-mi:“MI:0914”(association)	0.530
RRP8	NVL	psi-mi:“MI:0914”(association)	0.530
H1-4	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
ZNF2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
ZNF71	NVL	psi-mi:“MI:0914”(association)	0.530
RPL30	RRP8	psi-mi:“MI:0914”(association)	0.530
RPL7	ZBTB24	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF689	ZNF593	psi-mi:“MI:0914”(association)	0.530
THAP3	CASC3	psi-mi:“MI:0914”(association)	0.530
PPAN	PPM1G	psi-mi:“MI:0914”(association)	0.530
H1-4	RRP8	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
EWSR1	ZNF184	psi-mi:“MI:0915”(physical association)	0.370
ZNF184	CLIC1	psi-mi:“MI:0915”(physical association)	0.370
ZNF184	UBP1	psi-mi:“MI:0915”(physical association)	0.370
SOX6	ZNF184	psi-mi:“MI:0915”(physical association)	0.370
PPAN	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
RPL28	SDCBP	psi-mi:“MI:0914”(association)	0.350
CNBP	NOP56	psi-mi:“MI:0914”(association)	0.350
C6orf11	RRP8	psi-mi:“MI:0914”(association)	0.350
rl3_rl3l_human	NKRF	psi-mi:“MI:0914”(association)	0.350
RPL31	RPSA2	psi-mi:“MI:0914”(association)	0.350
RPS19	ZNF320	psi-mi:“MI:0914”(association)	0.350

BioGRID (79): ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-MS), ZNF184 (Affinity Capture-RNA), ZNF184 (Proximity Label-MS)

ESM2 similar proteins: A1YEP8, A1YFW2, A2RRD8, A2T6E3, A2T6V8, A2T7D2, A2T7F4, A2T812, A6NHJ4, O14709, O43309, O60765, P17036, P17097, P51814, P52738, Q02975, Q08ER8, Q0VGE8, Q12901, Q2M218, Q2M3X9, Q3KNS6, Q4V8A8, Q5RBX0, Q5RCD9, Q5VIY5, Q61751, Q6GQR8, Q6ZMS4, Q7TSH9, Q86Y25, Q8BQC8, Q8IYX0, Q8IZ26, Q8N9F8, Q8NF99, Q8TF39, Q8TF47, Q96N58

Diamond homologs: A0A087WUV0, Q96K75, Q99676, Q9HBT8, Q9UJL9, Q9UJN7, A0A1W2PQL4, A0JNB1, A0JPL0, A6NK53, A6QLU5, A6QPT6, A7MBI1, A8MT65, A8MUV8, A8MWA4, B2RXC5, B4DU55, B4DX44, E9PYI1, O14628, O75346, P0CH99, P0CI00, P17014, P17030, P17032, P17098, P51786, P85977, Q02386, Q06730, Q06732, Q0VAW7, Q12901, Q13360, Q14586, Q14588, Q14590, Q16587

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 79 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	11	31.7×	7e-13
Viral mRNA Translation	11	31.7×	7e-13
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	11	31.4×	7e-13
Selenocysteine synthesis	11	30.1×	9e-13
Eukaryotic Translation Termination	11	30.1×	9e-13
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	11	29.4×	9e-13
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	11	29.4×	9e-13
Formation of a pool of free 40S subunits	11	28.0×	1e-12

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	12	30.9×	1e-12
rRNA processing	10	19.7×	7e-09
ribosomal small subunit biogenesis	6	19.0×	5e-05
translation	12	17.1×	6e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

797 predictions. Top by Δscore:

Variant	Effect	Δscore
6:27456929:T:TC	acceptor_gain	1.0000
6:27457277:CCTTA:C	donor_loss	1.0000
6:27457278:CTTAC:C	donor_loss	1.0000
6:27457279:TTAC:T	donor_loss	1.0000
6:27457280:TA:T	donor_loss	1.0000
6:27457281:ACCT:A	donor_loss	1.0000
6:27457282:C:CT	donor_loss	1.0000
6:27457322:C:A	donor_gain	1.0000
6:27457406:CTTC:C	acceptor_gain	1.0000
6:27457407:TTC:T	acceptor_gain	1.0000
6:27457408:TC:T	acceptor_gain	1.0000
6:27457409:CC:C	acceptor_gain	1.0000
6:27457410:C:CA	acceptor_loss	1.0000
6:27472884:C:CA	donor_gain	1.0000
6:27472885:C:A	donor_gain	1.0000
6:27456927:CAT:C	acceptor_gain	0.9900
6:27456928:A:C	acceptor_gain	0.9900
6:27456929:T:C	acceptor_gain	0.9900
6:27457281:A:AC	donor_gain	0.9900
6:27457282:C:CC	donor_gain	0.9900
6:27457410:C:CC	acceptor_gain	0.9900
6:27457415:A:AC	acceptor_gain	0.9900
6:27472290:T:TA	donor_gain	0.9900
6:27472325:TGAAC:T	donor_gain	0.9900
6:27453261:C:CC	acceptor_gain	0.9800
6:27456840:A:AC	donor_gain	0.9800
6:27456841:C:CC	donor_gain	0.9800
6:27460525:A:C	donor_gain	0.9800
6:27467916:CAGAT:C	acceptor_gain	0.9800
6:27472306:AT:A	donor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000017423 (6:27422217 A>G,T), RS1000090715 (6:27422468 T>C), RS1000156694 (6:27424348 A>C,G), RS1000168871 (6:27449924 T>C), RS1000273017 (6:27425946 C>T), RS1000387990 (6:27434622 T>C), RS1000413996 (6:27421835 G>C), RS1000435463 (6:27435016 A>G), RS1000441639 (6:27470602 A>G), RS1000482522 (6:27422223 AAAG>A), RS1000535063 (6:27471049 A>C), RS1000537578 (6:27464738 C>A,T), RS1000573379 (6:27407540 C>T), RS1000590569 (6:27416609 A>G), RS1000745604 (6:27457587 T>C)

Disease associations

OMIM: gene MIM:602277 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

41 associations (top):

Study	Trait	p-value
GCST000433_1	Schizophrenia	1.000000e-08
GCST002463_3	Systemic lupus erythematosus	8.000000e-09
GCST003984_13	Parkinson’s disease	2.000000e-10
GCST004521_115	Autism spectrum disorder or schizophrenia	3.000000e-16
GCST004521_116	Autism spectrum disorder or schizophrenia	3.000000e-16
GCST004521_166	Autism spectrum disorder or schizophrenia	4.000000e-24
GCST004521_254	Autism spectrum disorder or schizophrenia	6.000000e-11
GCST004521_6	Autism spectrum disorder or schizophrenia	2.000000e-15
GCST004521_73	Autism spectrum disorder or schizophrenia	8.000000e-11
GCST004744_17	Lung adenocarcinoma	3.000000e-06
GCST004748_87	Lung cancer	2.000000e-11
GCST004748_88	Lung cancer	1.000000e-10
GCST004749_70	Lung cancer in ever smokers	8.000000e-09
GCST004749_71	Lung cancer in ever smokers	3.000000e-08
GCST004750_86	Squamous cell lung carcinoma	1.000000e-11
GCST004750_87	Squamous cell lung carcinoma	5.000000e-10
GCST004902_23	Parkinson’s disease	1.000000e-12
GCST005541_1	Sarcoidosis (Lofgren’s syndrome vs non-Lofgren’s syndrome)	1.000000e-16
GCST007429_15	Lung function (FVC)	1.000000e-22
GCST007430_73	Peak expiratory flow	1.000000e-48
GCST007431_140	Lung function (FEV1/FVC)	7.000000e-16
GCST007432_170	FEV1	3.000000e-35
GCST007537_1	Modic changes	3.000000e-06
GCST008664_5	Lung function (low FEV1 vs high FEV1)	5.000000e-11
GCST008921_6	Asthma and major depressive disorder	1.000000e-09
GCST008921_9	Asthma and major depressive disorder	3.000000e-08
GCST010002_50	Refractive error	4.000000e-34
GCST010083_343	Hemoglobin levels	3.000000e-15
GCST010142_16	Fish- and plant-related diet	2.000000e-10
GCST010142_19	Fish- and plant-related diet	4.000000e-10

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004312	vital capacity
EFO:0009718	peak expiratory flow
EFO:0004713	FEV/FVC ratio
EFO:0004314	forced expiratory volume
EFO:0004509	hemoglobin measurement
EFO:0008111	diet measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004530	triglyceride measurement
EFO:0004346	neuroimaging measurement
EFO:0009819	comparative body size at age 10, self-reported

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	2
Cyclosporine	increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
nickel sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
Leflunomide	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	decreases expression	1
Lead	affects methylation	1
Methyl Methanesulfonate	increases expression	1
Quercetin	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Urethane	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Aflatoxin M1	decreases expression	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer